Predictmedix AI Inc - 2025 Year End Corporate Update

A Defining Year Positioning Predictmedix AI at the Convergence of Quantum, AI, and Healthcare

Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company") concludes 2025 having delivered a year of disciplined execution across technology development, global investor engagement, and strategic advancement—positioning the Company for a pivotal growth phase in 2026 at the convergence of artificial intelligence, quantum-inspired computation, and digital healthcare.

Throughout 2025, Predictmedix AI enhanced the performance, scalability, and real-world effectiveness of its AI-driven health screening platforms while pioneering quantum-inspired computational enhancements. By leveraging hybrid quantum-classical algorithms, the Company has achieved sharper noise reduction, improved signal clarity, and more accurate screening across diverse populations—all while running efficiently on standard computing hardware without specialized quantum devices. These efforts are designed to elevate signal clarity, robustness, and adaptability beyond conventional AI approaches, establishing a strong trajectory as the Company enters 2026 with momentum, validated deployments, and increasing market visibility.

SmartHealth AI Stations

In 2025, Predictmedix AI surpassed 500,000 real-world scans, validating the scalability, resilience, and commercial readiness of its SmartHealth AI Stations across diverse environments and populations. As the first large-scale deployment of the Company's proprietary Core AI Engine, SmartHealth has proven the effectiveness of contactless, validated screening while continuously generating high-value real-world data.

This expanding dataset has strengthened model performance and supports the advancement of quantum-inspired enhancements. Using cutting-edge hybrid quantum-classical simulations, the SmartHealth AI Stations can model image noise and variability across diverse lighting, skin tones, and occlusions, delivering sharper detection clarity and reduced bias, all in real time on standard hardware.

Global Investor Engagement and European Roadshows

During 2025, Predictmedix AI significantly expanded engagement with the global investment community. The Company headlined a targeted European investor roadshow with events in Hungary, Croatia, and Serbia, engaging institutional investors, family offices, and strategic capital partners across Central and Southeastern Europe. These engagements increased awareness of Predictmedix AI's proprietary Core AI Engine, multi-vertical growth strategy, and global commercialization roadmap.